» Articles » PMID: 37920210

The Neuroprotective Effects of Liuwei Dihuang Medicine in the APP/PS1 Mouse Model Are Dependent on the PI3K/Akt Signaling Pathway

Overview
Journal Front Pharmacol
Date 2023 Nov 3
PMID 37920210
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is an age-related neurodegenerative disease that progressively impairs cognitive function and memory. The occurrence and development of Alzheimer's disease involves many processes. In response to the complex pathogenesis of AD, the Traditional Chinese medicine formula Liuwei Dihuang Pill (LWD) has been shown to improve the cognitive function of AD animal models. However, the active ingredients and mechanism of action of LWD have not been fully elucidated. In this study, network pharmacological analysis predicted 40 candidate compounds in LWD, acting on 227 potential targets, of which 185 were associated with AD. Through network pharmacological analysis, the mechanism of action of LWD therapy AD is related to the inhibition of inflammatory response, regulation of neuronal state, and autophagy. In this experiment, LWD was detected in the APP/PS1 transgenic mouse model. The objective was to observe the effects of LWD on hippocampal learning and memory ability, Aβ clearance, autophagy and inflammatory response in APP/PS1 mice. The results showed that LWD improved long-term memory and working memory in APP/PS1 mice compared with the WT group. At the same time, LWD can increase the expression of hippocampal autophagy biomarkers, reduce the precipitation of Aβ, and the activation of microglia and astrocytes. Its mechanism may be related to the regulation of the PI3K/Akt signaling pathway. Thus, we demonstrate for the first time that LWD has a neuroprotective effect on APP/PS1 mice and provide theoretical foundation for the development of a new clinical treatment for AD.

Citing Articles

Mechanism of traditional Chinese medicine in elderly diabetes mellitus and a systematic review of its clinical application.

Zhang Q, Hu S, Jin Z, Wang S, Zhang B, Zhao L Front Pharmacol. 2024; 15:1339148.

PMID: 38510656 PMC: 10953506. DOI: 10.3389/fphar.2024.1339148.

References
1.
Ma L, Zhao Z, Wang R, Zhang X, Zhang J, Dong W . Caloric restriction can improve learning ability in C57/BL mice via regulation of the insulin-PI3K/Akt signaling pathway. Neurol Sci. 2014; 35(9):1381-6. DOI: 10.1007/s10072-014-1717-5. View

2.
Smith M, Rottkamp C, Nunomura A, Raina A, Perry G . Oxidative stress in Alzheimer's disease. Biochim Biophys Acta. 2000; 1502(1):139-44. DOI: 10.1016/s0925-4439(00)00040-5. View

3.
Wang J, Lei X, Cheng X, Zhang X, Liu G, Cheng J . LW-AFC, a new formula derived from Liuwei Dihuang decoction, ameliorates behavioral and pathological deterioration via modulating the neuroendocrine-immune system in PrP-hAβPPswe/PS1 transgenic mice. Alzheimers Res Ther. 2016; 8(1):57. PMC: 5154149. DOI: 10.1186/s13195-016-0226-6. View

4.
Cai J, Xu L, Tang H, Yang Q, Yi X, Fang Y . The role of the PTEN/PI3K/Akt pathway on prognosis in epithelial ovarian cancer: a meta-analysis. Oncologist. 2014; 19(5):528-35. PMC: 4012960. DOI: 10.1634/theoncologist.2013-0333. View

5.
Heras-Sandoval D, Perez-Rojas J, Hernandez-Damian J, Pedraza-Chaverri J . The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration. Cell Signal. 2014; 26(12):2694-701. DOI: 10.1016/j.cellsig.2014.08.019. View